Related Experiment Videos
Muscarinic cholinergic receptors in human narcolepsy: a PET study
1Division of Advanced Technology for Medical Imaging, National Institute of Radiological Sciences, Chiba, Japan. sudo_y@nirs.go.jp
Objectives:
To investigate the function of the muscarinic cholinergic receptor (mAchR) in narcolepsy and the effects of pharmacotherapy on mAchRs.
Background:
Muscarinic neural transmission serves as the main executive system in REM sleep. Studies in canine narcolepsy reported an increase in mAchRs in the pons.
Methods:
The mAchRs of 11 drug naive/free patients with narcolepsy and 21 normal controls were investigated using PET with [11C]N-methyl-4-piperidylbenzilate ([11C]NMPB). Measurements were done in the pons, thalamus, striatum, and cerebral cortex. Seven of the 11 patients also underwent additional PET scans after the alleviation of symptoms by pharmacotherapy.
Results:
There were no differences in [11C]NMPB binding between the control and drug naive/free patients in all areas analyzed. At the time of on-medication PET scan, [11C]NMPB binding in the thalamus was decreased, but only to a small degree compared with that by anticholinergic drugs.
Conclusion:
The present results do not support the notion that the mAchR is the main site of action of pharmacotherapy in the marked clinical improvement of human cataplexy.
Insights
This study found no difference in muscarinic cholinergic receptors (mAchRs) in drug-free narcolepsy patients. Pharmacotherapy did not alter mAchRs, suggesting they are not the primary target for treating narcolepsy symptoms.
Area of Science:
- Neuroscience
- Sleep Medicine
- Pharmacology
Background:
- Muscarinic cholinergic receptors (mAchRs) are key in REM sleep regulation.
- Canine narcolepsy studies indicated elevated mAchRs in the pons.
Purpose of the Study:
- To examine muscarinic cholinergic receptor (mAchR) function in narcolepsy.
- To assess the impact of pharmacotherapy on mAchRs in narcolepsy patients.
Main Methods:
- Positron Emission Tomography (PET) with [11C]N-methyl-4-piperidylbenzilate ([11C]NMPB) was used.
- mAchRs were measured in the pons, thalamus, striatum, and cerebral cortex.
- 11 drug-naive/free narcolepsy patients and 21 controls were scanned; 7 patients were rescanned after treatment.
Main Results:
- No significant differences in [11C]NMPB binding were observed between controls and drug-naive/free narcolepsy patients.
- On-medication PET scans showed a slight decrease in thalamic [11C]NMPB binding.
- This decrease was minimal compared to effects seen with anticholinergic drugs.
Conclusions:
- The findings do not support mAchRs as the primary mechanism for pharmacotherapy-induced clinical improvement in human cataplexy.
- Further research is needed to elucidate the precise mechanisms of narcolepsy pharmacotherapy.